首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Rilmenidine and reflex renal sympathetic nerve activation in Wistar and hypertensive rats.
【2h】

Rilmenidine and reflex renal sympathetic nerve activation in Wistar and hypertensive rats.

机译:Wistar和高血压大鼠的瑞美尼定和反射性肾交感神经激活。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. This study sets out to examine the effect of rilmenidine administered systemically on basal and reflexly activated renal nerve activity in Wistar and stroke prone spontaneously hypertensive rats (SHRSP). 2. Animals were anaesthetized with chloralose/urethane, stimulating electrodes were placed on the brachial plexi and the renal nerves were isolated and put on recording electrodes. Both brachial nerves were stimulated electrically at 0.8, 1.6 and 3.2 Hz (15 V, 0.2 ms) in the absence and in the presence of rilmenidine given at 100 and 200 micrograms kg-1 i.v. in a cumulative manner. 3. Stimulation of the brachial nerves caused graded increases in blood pressure, heart rate and integrated renal nerve activity (P < 0.05) in both Wistar and SHRSP. Fast Fourier transformation of the renal nerve activity signal to generate a power spectrum demonstrated that both total power and percentage power at heart rate was higher in the SHRSP than Wistar (P < 0.05). Total power was raised during brachial nerve stimulation in both Wistar and SHRSP by some 200-300% (P < 0.05) but the percentage power at heart rate was decreased by some 60% (P < 0.01) in the Wistar but was raised by some 40-50% (P < 0.05) in the SHRSP. 4. Administration of rilmenidine caused dose-related decreases in blood pressure and heart rate and integrated renal nerve activity in both Wistar and SHRSP (all P < 0.05). Both doses of rilmenidine decreased (P < 0.05) the total power in the signal in both strains of rat by about one-half but the power occurring at heart rate only fell at the higher dose of compound in the Wistar, whereas in the SHRSP it was decreased by both doses by approximately 60-70%. In the presence of rilmenidine, coherence of the renal nerve signal was reduced in the Wistar and SHRSP and although the drug had no effect on phase difference in the Wistar, this parameter was decreased in the SHRSP by the low and high doses of rilmenidine (P < 0.05). 5. In the presence of 100 micrograms kg-1 rilmenidine, stimulation of the brachial nerves caused increases in total power in the Wistar and SHRSP (two to three fold, P < 0.05), together with a decrease (P < 0.05) in the percentage power occurring at heart rate in the Wistar, of some 60%, and an increase (P < 0.01) in the SHRSP, of some two to three times, which were very similar in magnitude and pattern to those obtained in the absence of the drug. Following the 200 micrograms kg-1 dose of rilmenidine, brachial nerve stimulation increased total power in the Wistar and SHRSP groups (P < 0.05) and whereas in the Wistar the percentage power at heart rate did not change in the SHRSP it was again increased in response to the electrical stimulation of the brachial plexus (P < 0.001) by between two to three fold. 6. These results showed that in both the Wistar and SHRSP rilmenidine depressed blood pressure, heart rate and integrated renal nerve activity. Moreover, rilmenidine did not affect the reflex activation of renal nerve activity via the somatosensory system although the characteristics within the power spectra underwent certain changes which might have a functional impact at the level to the kidney.
机译:1.这项研究着手研究在系统内给予瑞美尼定对Wistar和中风易发性自发性高血压大鼠(SHRSP)的基础和反射激活的肾神经活动的影响。 2.用氯醛/氨基甲酸乙酯麻醉动物,将刺激电极放置在臂丛上,分离肾神经并放置在记录电极上。在不存在和存在以100和200微克kg-1静脉内给予来美尼定的情况下,分别以0.8、1.6和3.2 Hz(15 V,0.2毫秒)电刺激两个臂神经。以累积的方式。 3.在Wistar和SHRSP中,刺激臂神经导致血压,心率和整合肾神经活动的分级升高(P <0.05)。肾神经活动信号的快速傅立叶变换以生成功率谱,表明SHRSP中的总功率和心率百分比功率均高于Wistar(P <0.05)。 Wistar和SHRSP均在臂神经刺激过程中将总功率提高了约200-300%(P <0.05),但在Wistar中,心率的百分比功率降低了约60%(P <0.01),但又增加了一些在SHRSP中占40-50%(P <0.05)。 4.在维斯塔和SHRSP中,使用来美替尼导致血压和心率的剂量相关降低,以及肾神经活动的整合(均P <0.05)。两种剂量的瑞美尼定均降低(P <0.05)两种大鼠品系中信号的总功率约一半,但在Wistar中,仅在较高剂量的化合物中,以心率出现的功率才下降,而在SHRSP中,两种剂量均降低约60-70%。在存在rilmenidine的情况下,Wistar和SHRSP中肾神经信号的相干性降低,尽管该药物对Wistar中的相差没有影响,但在SHRSP中,低剂量和高剂量的ridmenidine(P <0.05)。 5.在存在100微克kg-1瑞美替丁的情况下,刺激臂神经导致Wistar和SHRSP的总功率增加(2到3倍,P <0.05),同时降低(P <0.05)。 Wistar中出现的心率百分比功率大约为60%,SHRSP的增加百分比(P <0.01)为大约2到3倍,其大小和模式与不使用SHRSP时获得的功率非常相似。药品。在200微克kg-1剂量的利美替丁后,臂神经刺激增加了Wistar和SHRSP组的总功率(P <0.05),而在Wistar中,SHRSP中心率的百分比功率没有变化,但在SHRSP中又增加了。对臂丛神经电刺激的反应(P <0.001)减少两到三倍。 6.这些结果表明,在Wistar和SHRSP中,瑞美尼定均降低了血压,心率和整合了肾神经的活动。此外,尽管功率谱内的特征发生了某些变化,可能会对肾脏水平产生功能性影响,但瑞美替丁并未影响通过体感系统对肾神经活动的反射激活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号